Jean Boulle Group Receives US$47 million Cash Investment from a New Major Strategic Investor in its Proprietary VDYNE Technology – Set to Disrupt the Market for Heart Valve Replacement

Luxembourg 24 October 2022 The Jean Boulle Group (“the Group”) is pleased to announce a US$47 million cash investment (“the Investment”) in Jean Boulle Medtech’s proprietary VDYNE heart valve technology from a new major strategic investor. The proceeds of the Investment will be used to accelerate human clinical trials of VYDNE’s novel prosthetic tricuspid valve which…